Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORANE vs SUPRANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.
Suprane (desflurane) is a volatile general anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptor function, leading to neuronal hyperpolarization and depression of central nervous system activity.
Induction and maintenance of general anesthesia,Sedation for mechanical ventilation in intensive care
Induction and maintenance of general anesthesia for inpatient and outpatient surgery in adults and children,Maintenance of anesthesia in pediatric patients
Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.
Induction: 0.5-3% inspired concentration in oxygen or oxygen/nitrous oxide mixture; Maintenance: 0.5-2% inspired concentration. Administered via inhalation using a calibrated vaporizer.
Context-sensitive half-life: 2-5 minutes after short exposure; prolonged to 30-60 minutes after prolonged administration due to accumulation in fat and muscle. Terminal elimination half-life: 0.5-1 hour.
Context-sensitive half-life: 2-5 minutes after brief administration; prolonged to 20-40 minutes after prolonged administration due to slow release from fat stores.
Primarily hepatic via CYP2E1; also undergoes glucuronidation and defluorination.
Minimal hepatic metabolism (less than 0.02%) via CYP2E1; primarily eliminated unchanged by the lungs.
Primarily exhaled unchanged via lungs (>95%); <5% metabolized in liver to fluoride ions and other metabolites, which are excreted renally.
Primarily eliminated by the lungs with minimal metabolism (<5%). Less than 0.2% of the absorbed dose is excreted renally as unchanged drug.
~40% bound to plasma proteins (mainly albumin).
~60% bound to serum proteins, primarily albumin and lipoproteins.
Vd: 1.5-2.0 L/kg, reflecting distribution to highly perfused tissues (brain, heart, liver, kidneys) and subsequent redistribution to muscle and fat.
Vd: 0.6-0.8 L/kg at steady state; large distribution into lipid-rich tissues.
100% via inhalation.
Inhalation: ~100% due to complete absorption from the lungs; no oral bioavailability is clinically relevant.
No adjustment required.
No dose adjustment required for renal impairment; Suprane is minimally metabolized and renally excreted.
Use with caution; reduce dose in severe hepatic impairment (Child-Pugh C).
No specific dose adjustment for Child-Pugh class A or B; caution in severe hepatic impairment (Child-Pugh C) due to potential decreased clearance, consider reduced maintenance concentrations.
Induction: 1-4% inspired; Maintenance: 0.5-2% inspired.
Induction: 3% inspired concentration in oxygen (or oxygen/nitrous oxide) for unpremedicated children, titrated to effect; Maintenance: 1-2% inspired concentration. Adjust based on age and response.
Reduce inspired concentrations by 25-50% due to increased sensitivity.
Elderly patients (≥65 years): Reduce induction and maintenance concentrations by 20-50% due to increased sensitivity and slower recovery; typical maintenance 0.5-1.5% inspired.
None
Suprane is contraindicated for induction of anesthesia in pediatric patients due to a high incidence of laryngospasm, coughing, breath-holding, and hypoxia.
Risk of malignant hyperthermia,Respiratory depression,Hypotension,Hepatotoxicity with repeated use or in susceptible patients,Nephrotoxicity due to fluoride ions
Risk of malignant hyperthermia,Risk of perioperative hypersensitivity reactions including anaphylaxis,Risk of QT prolongation and torsades de pointes,Risk of hepatotoxicity in patients with previous exposure to halogenated anesthetics,May cause dose-dependent respiratory depression,Use caution in patients with increased intracranial pressure,May cause hypotension and bradycardia
Known hypersensitivity to isoflurane or other halogenated agents,Known or suspected genetic susceptibility to malignant hyperthermia
Known or suspected susceptibility to malignant hyperthermia,Known hypersensitivity to desflurane or other halogenated anesthetics,Induction of anesthesia in pediatric patients,Patients with a history of hepatitis or unexplained jaundice after previous halogenated anesthetic use
No specific food interactions are documented for isoflurane. However, patients should follow standard preoperative fasting guidelines (e.g., NPO for 8 hours prior to elective surgery) to reduce aspiration risk during anesthesia.
No direct food interactions; fasting is required before anesthesia (typically NPO for 6-8 hours for solids, 2 hours for clear liquids) to reduce aspiration risk during induction.
FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters: known to cause dose-dependent maternal hypotension and uterine relaxation, which may reduce placental perfusion; use only if clearly needed.
Sevoflurane (Suprane) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. Use in the first trimester should be avoided unless essential. In the second and third trimesters, it is used for general anesthesia; however, it may produce uterine relaxation and fetal depression. Prolonged or repeated exposure should be avoided due to potential neurotoxicity in the developing fetus.
Isoflurane is excreted into breast milk in minimal amounts; M/P ratio is approximately 0.85. After inhalational anesthesia, the concentration in milk is low and rapidly cleared. The American Academy of Pediatrics considers it compatible with breastfeeding. However, it is recommended to discard milk for 24 hours post-procedure due to sedation and potential metabolites.
Sevoflurane is rapidly eliminated; trace amounts may be excreted into breast milk. The M/P ratio is not established. Due to rapid clearance, the risk to the infant is low. The manufacturer recommends discontinuing breastfeeding for 24 hours after anesthesia to minimize exposure.
No specific dose adjustment is required for pregnancy, but due to increased volume of distribution and decreased protein binding, a slightly lower dose may achieve desired anesthetic depth. Maintenance of uterine perfusion pressure is critical; avoid hypotension. The minimum alveolar concentration (MAC) is decreased by approximately 25% in pregnancy.
No specific dose adjustments are recommended for sevoflurane during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, decreased protein binding) may require higher induction doses and more rapid adjustments. Maintenance doses should be titrated to effect with careful monitoring of maternal vital signs and fetal heart rate.
FORANE (isoflurane) is a potent inhalational anesthetic with rapid onset and offset due to low blood-gas solubility. It causes dose-dependent respiratory depression and hypotension via peripheral vasodilation. Monitor end-tidal CO2 and arterial blood pressure closely. Avoid in patients with known or suspected malignant hyperthermia susceptibility. Use a calibrated vaporizer to deliver precise concentrations (1-3% for induction, 0.5-2% for maintenance).
Suprane (desflurane) has a low blood-gas partition coefficient (0.42) enabling rapid induction and emergence. It is a potent bronchodilator but can cause airway irritation and coughing during induction; avoid in pediatric mask inductions. Contraindicated in patients with known or suspected malignant hyperthermia susceptibility. Requires a calibrated vaporizer due to high vapor pressure (near-ambient). Can produce dose-dependent hypotension and respiratory depression.
This medication is for hospital use only and will be administered by an anesthesia provider.,You may experience drowsiness, dizziness, or confusion after waking from anesthesia.,Do not drive or operate machinery for at least 24 hours after receiving this drug.,Inform your doctor if you have a personal or family history of malignant hyperthermia.,Report any muscle rigidity, fever, or dark urine to your healthcare provider immediately.
You will be given this anesthetic gas through a mask or breathing tube to keep you asleep during surgery.,You may experience a temporary sore throat or cough after waking up.,Common side effects include nausea, vomiting, and shivering as you recover.,You should not drive or operate machinery for at least 24 hours after anesthesia.,Inform your doctor if you have any personal or family history of malignant hyperthermia.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORANE vs SUPRANE, answered by our medical review team.
FORANE is a Inhalational Anesthetic that works by Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.. SUPRANE is a Inhalational Anesthetic that works by Suprane (desflurane) is a volatile general anesthetic that potentiates GABA-A receptor activity and inhibits NMDA receptor function, leading to neuronal hyperpolarization and depression of central nervous system activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORANE and SUPRANE depend on the specific clinical indication. These are both Inhalational Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORANE is: Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.. The standard adult dose of SUPRANE is: Induction: 0.5-3% inspired concentration in oxygen or oxygen/nitrous oxide mixture; Maintenance: 0.5-2% inspired concentration. Administered via inhalation using a calibrated vaporizer.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORANE and SUPRANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORANE is classified as Category C. FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters. SUPRANE is classified as Category C. Sevoflurane (Suprane) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects, but there are no adequate and well-controlled studies in . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.